

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

NCT03936335

Status RECRUITING
Sponsor Regeneron Pharmaceuticals
Enrollment 3,930 participants

Key Eligibility Criteria

Inclusion (2)

- Continuous medical and pharmacy benefit coverage for at minimum 6 months prior to and including the estimated LMP
- Diagnosis code indicative of AD in the period from up to 1 year prior to the estimated LMP through the end of the pregnancy

Locations (1 total)

Regeneron Research Site, Boston, Massachusetts, United States